相关临床试验
273
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1968
进行中（未招募）
5
1.8%
已完成
209
76.6%
尚未招募
1
0.4%
招募中
17
6.2%
终止
18
6.6%
Unknown
21
7.7%
撤回
2
0.7%
暂无批准数据
- PerZeption Inc. has received a Phase I SBIR grant from the National Eye Institute to develop an achromatic and chromatic photostress recovery test for age-related macular degeneration. - The Boston-based company will run the study with researchers at the Brunson Center for Translational Vision Research at the University of California, Irvine. - The funded work aims to characterize the full post-light-exposure recovery curve on PerZeption's Angular Indication Measurement platform rather than a single recovery time point. - Phase I NEI SBIR awards carry up to $323,090 in total costs, and the project is intended to generate feasibility data supporting a regulatory pathway.
- Curative Biotechnology received Canadian patent allowance for a novel pharmacological target to treat retinal degenerative diseases, developed by the National Eye Institute. - The patent includes 22 claims covering topical ocular delivery approaches for metformin-based formulations, aligning with the company's eye drop development strategy. - The company plans to expand its metformin-based program into canine retinal diseases and advance human clinical trials for age-related macular degeneration in 2026. - This patent strengthens Curative's global intellectual property portfolio for its ophthalmology platform under exclusive worldwide licensing from the NIH.
- EssilorLuxottica received FDA market authorization for Essilor Stellest lenses, marking the first spectacle lens clinically proven to slow myopia progression in children aged 6-12 years. - Clinical trial data demonstrated a 71% reduction in myopia progression and 53% reduction in axial length elongation compared to single-vision control lenses over two years. - The authorization addresses a growing public health concern, as myopia affects 40% of the US population and is projected to impact half the world's population by 2050. - The lenses offer a lower-risk alternative to contact lenses for pediatric myopia management, with no serious adverse events reported in clinical trials.
- iVeena Delivery Systems received a $2 million Phase 2 SBIR grant from the National Eye Institute to develop IVMED-85, a novel topical eye drop for pediatric myopia. - The preservative-free therapy works through a unique mechanism that enhances corneal and scleral crosslinking while avoiding side effects of current off-label treatments. - With over 20 million affected children in the US and no FDA-approved therapies available, this represents a significant unmet medical need. - The company submitted an IND application to the FDA in June 2025 and plans to initiate a multinational Phase 2 study.
- NIH researchers have discovered that reserpine, a decades-old blood pressure medication, can protect photoreceptor cells from degeneration in inherited retinal dystrophies regardless of the specific genetic mutation involved. - The drug showed particularly strong protective effects in female subjects compared to males in a rat model of retinitis pigmentosa, suggesting potential for sex-specific therapeutic approaches in treating blinding diseases. - Reserpine offers advantages as a small molecule therapy that can be delivered directly to the eye at low doses, potentially providing a faster path to treatment than gene-specific therapies for the more than 1,000 mutations that can cause inherited retinal diseases.
- Researchers at NIH have developed eye drops containing small peptides derived from pigment epithelium-derived factor (PEDF) that successfully slowed vision loss in animal models of retinitis pigmentosa. - The peptide formulations, particularly H105A, preserved up to 75% of photoreceptors in treated mice and maintained functional vision, while reaching the retina within 60 minutes of application without toxicity. - While not a cure, these PEDF-based eye drops show promise for treating various degenerative retinal diseases, including retinitis pigmentosa and dry age-related macular degeneration, with researchers now planning human clinical trials.
- The University of Colorado Anschutz Medical Campus will receive up to $46 million from ARPA-H to advance vision-restoring human whole eye transplantation. - The project aims to achieve the first successful vision recovery in six human whole eye transplants by 2030, addressing optic nerve regeneration challenges. - The multi-disciplinary team includes experts from Johns Hopkins, University of Wisconsin, and the National Eye Institute, focusing on innovative technologies. - The Foundation Fighting Blindness will strategically align the consortium's progress with program requirements, driving advancements in treating blinding diseases.
• The University of North Dakota (UND) research team has been approved to conduct clinical trials for the Pediatric Eye Disease Group (PEDIG), focusing on innovative treatments for childhood eye conditions. • The trials will assess the effectiveness of virtual reality (VR) headsets as a novel approach to treating amblyopia, also known as lazy eye, in children aged 4 to 12. • These PEDIG studies, funded by the National Eye Institute (NEI) and the National Institutes of Health (NIH), aim to compare VR therapy with traditional eye patching for amblyopia treatment. • The research could potentially change the standard of care for amblyopia, offering a more engaging and effective alternative to conventional methods.
- Long-term, low-dose valacyclovir reduces the risk of new or worsening eye disease by 26% in patients with herpes zoster ophthalmicus (HZO). - The Zoster Eye Disease Study (ZEDS) found a 30% reduction in flare-ups at 12 months and 28% at 18 months with antiviral therapy. - The treatment also shortened pain duration and decreased the need for medications like pregabalin and gabapentin. - Experts emphasize shingles vaccination with Shingrix for adults 50 and older, and immunocompromised adults 19 and older.
- The University of Arkansas for Medical Sciences (UAMS) has received a $2.2 million grant from the National Eye Institute (NEI). - The grant will fund research into how modulating the immune response through efferocytosis can benefit patients with retinopathy. - Dr. Abdel Fouda's lab will lead the study, exploring methods to enhance myeloid cell-mediated efferocytosis in treating retinopathy. - The research aims to develop new therapies for ischemic and trauma-induced retinopathy by understanding efferocytosis' role.
